Biocon Biologics gets US FDA nod for biosimilar version of eye treatment drug Eylea ...Middle East

Bengaluru:  Biocon Biologics said on Tuesday that the US Food and Drug Administration (US FDA) has approved the company’s first-to-file application for Yesafili, a biosimilar drug for treating eye ailments. The company said the medicine is similar to the reference product Eylea (aflibercept) intended for the treatment of neovascular age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion, visual impairment due to diabetic macular oedema and visual impairment due to myopic choroidal neovascularisation. Studies demonstrate that Yesafili matches Eylea in quality, safety, and efficacy, it added. “The FDA approval of Yesafili (aflibercep

Hence then, the article about biocon biologics gets us fda nod for biosimilar version of eye treatment drug eylea was published today ( Tuesday 21/05/2024 - 12:13 PM ) and is available on News room odisha ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Biocon Biologics gets US FDA nod for biosimilar version of eye treatment drug Eylea )

Also on site :

• Wayfair’s ‘Compact’ Chenille Loveseat Is a ‘Stylish’ Way to Add ‘Cozy’ Seating to Small Spaces, Now 65% Off
• ‘The Song of Scorpions,’ ‘Qissa’ Director Anup Singh Sets Mumbai Film ‘Lasya: The Gentle Dance’ (EXCLUSIVE)
• Ukraine-Russia war latest: Putin fires nuclear-capable missile that could reach US days after CIA chief’s visit